Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11801523 | 0.87 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL11310007 | 0.83 | POLB (0.50) | POLBTSHRGAASMN1; SMN2 | |
| SCHEMBL21828164 | 0.83 | CYP3A4 (0.41) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL194844 | 0.83 | POLB (0.42) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL14561060 | 0.83 | POLB (0.41) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL28817638 | 0.83 | CYP3A4 (0.40) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL30008276 | 0.82 | POLB (0.40) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL7617677 | 0.82 | GAA (0.41) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL13847695 | 0.81 | CYP3A4 (0.42) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL1052265 | 0.81 | POLB (0.40) | POLBCYP3A4CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117962437-A | Electromagnetic radiation-resistant PVC co-extrusion foaming plate and preparation method thereof | 淮阴工学院 | 2024-05-03 | — | — | CN | claimed |
| CN-110945075-B | Polyester resin composition and method for producing same | 东丽株式会社 | 2022-03-25 | — | — | CN | claimed |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | claimed |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | claimed |
| EP-2882030-B1 | NON-AQUEOUS ELECTROLYTE AND ENERGY STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2017-06-21 | — | — | EP | claimed |
| EP-1550683-B1 | POLYESTER RESIN COMPOSITIONS, POLYESTER FILM, AND MAGNETIC RECORDING MEDIUM | TORAY INDUSTRIES (JP) | 2017-04-26 | — | — | EP | claimed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | claimed |
| JP-2000500758-A | — | — | 2000-01-25 | — | — | JP | claimed |
| EP-0862575-A1 | NOVEL GERANYLGERANYL-DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND RELATED PHARMACEUTICAL COMPOSITIONS | LABORATORI BALDACCI Spa (IT) | 1998-09-09 | — | — | EP | claimed |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12479791-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4318630-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12401060-B2 | Nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-08-26 | — | — | US | disclosed |
| US-4591651-A | Process for directly converting an aldehyde into an ethylene ester | AGRIFURANE S.A. (FR) | 1986-05-27 | — | — | US | disclosed |
| EP-0080889-A1 | Herbicidal compositions containing and method using phosphonoalkanoic acids, esters and salts thereof | PHILIP A. HUNT CHEMICAL CORPORATION (US) | 1983-06-08 | — | — | EP | disclosed |
| US-4151172-A | Phosphonoacyl prolines and related compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-3935271-A | INSECTICIDE | SANDOZ LTD. (CH) | 1976-01-27 | — | — | US | disclosed |
| US-3932483-A | INSECTICIDES | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479791-B2 | Cationic lipid | LIPC, NPC1, LPCAT1 | POLB 477/4885CYP3A4 4326/4885CYP2C9 2014/4885 |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | FFAR1, CYP2S1, CYP1B1 | POLB 4485/4885CYP3A4 67/4885CYP2C9 190/4885 |
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TNNT2, TNNC1, TNNI3 | POLB 3016/4885CYP3A4 4878/4885CYP2C9 3737/4885 |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | SLC75A1, SLC18A3, SLC8A1 | POLB 4180/4885CYP3A4 3505/4885CYP2C9 4174/4885 |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | FFAR1, CYP2S1, FFAR3 | POLB 4436/4885CYP3A4 66/4885CYP2C9 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.